JHVEPhoto Eli Lilly ( NYSE: LLY ) said Friday it expects to report Q2 IPR&D pre-tax charges of around $154M, amounting to approximately $0.14 a share on a GAAP and non-GAAP basis, according to Bloomberg. Analysts were expecting Lilly to report Q2 GAAP EPS of $2.
76 and non-GAAP EPS of $2.81. The drugmaker is expected to release its earnings report on Aug.
8. More on Eli Lilly What Eli Lilly Is Getting With The Acquisition Of Morphic Holding Wall Street Lunch: Merger Monday In All Its Glory Eli Lilly Targets IBD, Takes Calculated Gamble With $3.2bn Morphic Deal These are the weight loss drug stocks with the most upside - SA Sentiment Survey SA subscribers pitch stocks that could potentially replace Tesla in Magnificent 7.
